Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya.
Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya.
Jpn J Clin Oncol. 2020 Dec 16;50(12):1364-1369. doi: 10.1093/jjco/hyaa151.
Current guidelines do not recommend that sentinel lymph node biopsy is routinely performed for ductal carcinoma in situ; thus, indications for sentinel lymph node biopsy in patients with ductal carcinoma in situ remain controversial. In this study, we investigated whether sentinel lymph node biopsy can be safely omitted when ductal carcinoma in situ has been diagnosed by preoperative biopsy.
We retrospectively analysed sentinel lymph node metastasis rates and upstaging to invasive cancer in surgical specimens, performed receiver operating characteristic analysis for ductal carcinoma in situ lesion size and assessed correlations with preoperative clinicopathological factors of 277 patients with ductal carcinoma in situ diagnosed by preoperative biopsy at our institution.
Among 277 patients with sentinel lymph node biopsy, six (2.2%) had sentinel lymph node metastasis. All six were upstaged to invasive cancer by pathological examination of surgical specimens. In total, 69 patients (24.9%) were upstaged to invasive cancer. The mean size of ductal carcinoma in situ lesions on preoperative imaging was significantly larger for the 69 upstaged patients (50.0 mm) than for the non-upstaged patients (34.4 mm; P < 0.0001). Of the 277 patients with sentinel lymph node biopsy, 117 (42.2%) had preoperative ductal carcinoma in situ lesions <31.8 mm, which was identified as the optimal cut-off size by receiver operating characteristic analysis. Of these 117 patients, 96 (82.1%, 95% confidence interval: 73.9-88.5%) could be safely omitted from sentinel lymph node biopsy because all of them remained as ductal carcinoma in situ and had negative sentinel lymph nodes at surgery.
Size of ductal carcinoma in situ lesions on preoperative diagnostic imaging is a predictor of diagnosis of invasive cancer on pathological examination of surgical specimens. Sentinel lymph node biopsy may be unnecessary in ductal carcinoma in situ diagnosed by preoperative biopsy in patients with small lesions.
目前的指南不建议常规对导管原位癌行前哨淋巴结活检,因此导管原位癌患者行前哨淋巴结活检的适应证仍存在争议。在本研究中,我们研究了当术前活检诊断为导管原位癌时,是否可以安全地省略前哨淋巴结活检。
我们回顾性分析了 277 例术前活检诊断为导管原位癌患者的前哨淋巴结转移率和升级为浸润性癌的比例,对术前影像学检查中导管原位癌病变大小进行了受试者工作特征曲线分析,并评估了其与术前临床病理因素的相关性。
在 277 例行前哨淋巴结活检的患者中,有 6 例(2.2%)出现前哨淋巴结转移。所有 6 例均通过手术标本的病理检查升级为浸润性癌。共有 69 例(24.9%)患者升级为浸润性癌。术前影像学检查中,升级为浸润性癌患者的导管原位癌病变平均大小(50.0mm)明显大于未升级患者(34.4mm;P<0.0001)。在 277 例行前哨淋巴结活检的患者中,117 例(42.2%)术前导管原位癌病变<31.8mm,这在受试者工作特征曲线分析中被确定为最佳截断值。在这 117 例患者中,96 例(82.1%,95%置信区间:73.9%~88.5%)可以安全地省略前哨淋巴结活检,因为所有患者仍为导管原位癌,且手术时前哨淋巴结阴性。
术前诊断性影像学检查中导管原位癌病变的大小是预测手术标本病理检查中浸润性癌诊断的指标。对于术前活检诊断为导管原位癌且病变较小的患者,前哨淋巴结活检可能不是必需的。